KeMyth Biotech Company was established in July 2015. We aim to bring research into industrial products for human health. Currently the following main projects are in progress:
(1) Klebsiella pneumoniae serotype K1/K2 rapid testing cassette (Taiwan FDA License No.007019): Has been used by medical centers in Taiwan, published in leading journals (2016, J Clin Microbiol, 54:3018-21; 2019, Gut Pathog, 11:11; 2020, Gut Pathog, 12:34; 2022, JMII, 55:180-181), and earned the 13th National Innovation Award in Taiwan.
(2) Antibiotic testing and screening system against superbugs: Has been published in leading journals (2017, J Antimicrob Chemother, 72:3302-16; 2020, Int J Antimicrob Agents, 55:105918) and has been used by research institutes and pharmaceutical companies in Taiwan, USA, France, Japan etc. The U.S. patent number is US 10,760,110 B2.
(3) A candidate drug to control type 2 diabetes, atherosclerosis, and body weight: The research results have been published in a leading journal (2020, Cells, 9(5):E1183) and the U.S. patent number is US 10,287,328 B2.
(4) Natural food: Exquisite Ginger Tea; Cranberry effervescent tablet; Natural Capsules (Quintessential Ginger, Okra & Bitter Gourd Extract, Artichoke & Ginger Extract, Echinacea purpurea Extract & Vitamin C).
(5) Skin care: Purifying Hydration Mask.